These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 971716)

  • 1. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
    van Boxtel CJ; Wilson JT; Lindgren S; Sjöqvist F
    Eur J Clin Pharmacol; 1976 Feb; 9(4):327-32. PubMed ID: 971716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
    Harman AE; Priestly BG; Frewin DB
    Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of antipyrine kinetics by measurement in saliva.
    Fraser HS; Mucklow JC; Murray S; Davies DS
    Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
    Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
    Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of salivary concentration data to pharmacokinetic studies with antipyrine.
    Meffin PJ; Williams RL; Blaschke TF; Rowland M
    J Pharm Sci; 1977 Jan; 66(1):135-7. PubMed ID: 833730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.
    Chang RL; Wood AW; Dixon WR; Conney AH; Anderson KE; Eiseman J; Alvares AP
    Clin Pharmacol Ther; 1976 Aug; 20(2):219-26. PubMed ID: 947654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of antipyrine kinetics from saliva or plasma: influence of age.
    Jorquera F; Almar MM; Jimeno A; González-Sastre M; González-Gallego J
    J Pharm Biomed Anal; 1995 Aug; 13(9):1141-5. PubMed ID: 8573640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary antipyrine half-life during injectable progestagen contraception.
    Joshi JV; Gupta KC; Hazari KT; Gokral J; Pohujani S; Satoskar R
    Clin Pharmacokinet; 1986; 11(2):171-5. PubMed ID: 3956050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal variations of antipyrine half-life in man.
    Vesell ES; Shively CA; Passananti GT
    Clin Pharmacol Ther; 1977 Dec; 22(6):843-52. PubMed ID: 923179
    [No Abstract]   [Full Text] [Related]  

  • 15. A sensitive gas-chromatographic assay using a nitrogen-phosphorus detector for determination of antipyrine and aminopyrine in biological fluids.
    Shively CA; Simons RJ; Vesell ES
    Pharmacology; 1979; 19(5):228-36. PubMed ID: 538077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.
    Danhof M; de Groot-van der Vis E; Breimer DD
    Pharmacology; 1979; 18(4):210-23. PubMed ID: 461498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.
    Huffman DH; Shoeman DW; Azarnoff DL
    Biochem Pharmacol; 1974 Jan; 23(2):197-201. PubMed ID: 4813341
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of fever on antipyrine metabolism in children.
    Forsyth JS; Moreland TA; Rylance GW
    Br J Clin Pharmacol; 1982 Jun; 13(6):811-5. PubMed ID: 7093111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma antipyrine half-life can be determined from urine data.
    Atiba JO; Taylor G; Pershe RA; Blaschke TF
    Br J Clin Pharmacol; 1987 Jun; 23(6):715-9. PubMed ID: 2440468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.